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Abstract
Background: Non-pathological cognitive ageing is a distressing condition affecting an increasing
number of people in our 'ageing society'. Oxidative stress is hypothesised to have a major role in
cellular ageing, including brain ageing.
Results: Associations between cognitive ageing and 325 single nucleotide polymorphisms (SNPs),
located in 109 genes implicated in oxidative stress and/or cognition, were examined in a unique
cohort of relatively healthy older people, on whom we have cognitive ability scores at ages 11 and
79 years (LBC1921). SNPs showing a significant positive association were then genotyped in a
second cohort for whom we have cognitive ability scores at the ages of 11 and 64 years (ABC1936).
An intronic SNP in the APP gene (rs2830102) was significantly associated with cognitive ageing in
both LBC1921 and a combined LBC1921/ABC1936 analysis (p < 0.01), but not in ABC1936 alone.
Conclusion: This study suggests a possible role for APP in normal cognitive ageing, in addition to
its role in Alzheimer's disease.
Background
Individuals differ in their cognitive skills, and in how
much these cognitive skills change as people grow older.
That is, there are individual differences in the trait (or
level) of intelligence, and in the age-related change (or tra-
jectory). We have previously shown that about 50% of the
variance in trait intelligence is stable from the age of 11 to
the age of 79[1]. In both the trait and the age-related
change, the majority of the between-individual variation
is accounted for by a common factor of general cognitive
ability (or g)[2,3]. Both mild intellectual impairment (low
trait intelligence) and accelerated age-related cognitive
decline (increased downward trajectory in intelligence)
have a major impact on society, because of the large
number of individuals involved who have limited inde-
pendence. In our increasingly 'ageing society', disabilities
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linked to cognitive ageing are a growing medical and
social problem.
There are environmental and genetic contributions to
individual differences in trait intelligence and cognitive
ageing[4,5]. Genetic influences account for more than
50% of the variability in adult cognitive abilities[6]. We
have shown that genetic variation in some specific genes,
e.g. APOE is associated with change in cognitive ability
with age, but not with the stable trait of intelligence[7].
Therefore, it is likely that some genetic variants are associ-
ated with life-long cognitive abilities and others specifi-
cally with variance in age-related cognitive decline. The
search for genetic contributions to cognitive ageing can be
guided by focussing on mechanisms that affect brain age-
ing[5].
Oxidative stress is hypothesised to be a significant con-
tributor to cellular ageing. The free radical theory of age-
ing predicts that, with increasing age, free radicals, reactive
by-products of oxidative metabolism, damage macromol-
ecules such as DNA, protein and lipids[8,9]. Support for
the free radical hypothesis of ageing comes from a wide
variety of sources, including analyses of mutations and
transgenic animals (for recent reviews see[10,11]). The
brain is particularly vulnerable to oxidative damage as a
result of its high aerobic metabolism and high concentra-
tions of polyunsaturated fatty acids that are susceptible to
lipid peroxidation [12-15].
Oxidative damage to mitochondrial DNA accumulates at
a ten-fold higher rate than nuclear DNA, although its pre-
cise significance to ageing remains controversial[16,17].
The constant leak of reactive oxygen species from mito-
chondria increases with age, and deficiency of both mito-
chondrial and cytoplasmic superoxide dismutase are
associated with neurodegeneration due to oxidative dam-
age [18-20]. A role for oxidative stress has been proposed
both in Alzheimer's disease (AD), associated with amy-
loid plaques[21,22], and in Parkinson's disease, with the
presence of iron and auto-oxidised monoamines[23]. A
role for oxidative stress has also been proposed in mild
cognitive impairment[24,25]. Non-pathological cognitive
ageing was found to be related to differences in oxidative
stress (measured, for example, by thiobarbituric acid reac-
tive substances) in a large community study of older peo-
ple[26]. It is also implicated in the "common cause
hypothesis of ageing": the recent finding that physical and
cognitive capabilities are highly correlated in old age[27].
Expression profiling of large gene arrays in adult and aged
mouse brain also supports a role for oxidative damage in
cognitive ageing[28,29]. Lee et al[28] examined the
expression profiles in neocortex and cerebellum of 6,347
genes in adult (5 months) and aged (30 months) mice. In
both brain regions, gene expression profiles showed
increased inflammatory response and oxidative stress
gene expression in the older mice. These authors con-
cluded that oxidative stress is an important and perhaps
underlying cause of the ageing process in post-mitotic
(neural) tissues. In a similar study, Jiang et al[29] probed
over 11,000 genes in cortex and hypothalamus in 2
month and 22 month old mice and found altered expres-
sion for 98 genes (0.9%) in cortex, about 20% of which
were also altered in hypothalamus. Significant changes (at
least two-fold) were found in a variety of proteins, includ-
ing eight concerned with oxidative stress response.
We previously identified associations between common
functional polymorphisms in genes involved in AD or
oxidative stress and cognitive ageing[7,30,31]. However,
these studies all involved genotyping small numbers of
polymorphisms in a small sample of genes. Technology is
now available to genotype easily much larger numbers of
polymorphisms. The aim of the present study was to
investigate the influence of genetic variation in genes pri-
marily related to oxidative stress and antioxidant defences
in two cohorts of relatively healthy older individuals.
These are the Lothian Birth Cohort of 1921 (LBC1921)
and the Aberdeen Birth Cohort of 1936 (ABC1936), on
whom cognitive ability test scores are available at age 11
and in later life; that is, they have data on the lifetime trait
of intelligence, and lifetime cognitive change[32]. These
cohorts form a unique resource to test for genes associated
with cognitive ageing. Both cohorts took an identical
mental ability test at age 11 and a different but overlap-
ping series of cognitive ability tests at either age 79
(LBC1921) or age 64 (ABC1936)[32]. To utilise this
resource a candidate gene genetic association study was
performed by genotyping 387 SNPs in 444 members of
LBC1921. We have ~80% power to detect an effect size of
3% at a type-1 error rate of 0.01. Replication of possible
associations is important. Therefore, SNPs that showed a
positive association with either cognitive ability at age 11
or cognitive ageing were then genotyped in 485 members
of ABC1936.
Results
384 SNPs were selected for genotyping by the Golden-
Gate™ assay. A multiplex assay was successfully designed
for 322 SNPs (83.9%). 437 (261 women, 176 men) of the
444 LBC1921 subjects (98.4%) were successfully geno-
typed for at least 316 SNPs. Genotyping data were
obtained, from both samples, for 15 of the 16 subjects
who were genotyped in duplicate and no discrepancies
were identified. Three further SNPs were genotyped by
TaqMan® technology in 424–434 of the subjects. In sum-
mary 325 SNPs were genotyped in 420–437 subjects. 86
SNPs (26.5%) were monomorphic in LBC1921.BMC Genetics 2007, 8:43 http://www.biomedcentral.com/1471-2156/8/43
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LBC1921
Childhood cognitive ability in LBC1921
There was a nominally significant association between
three SNPs and age 11 Moray House Test (MHT) score:
CTSZ, rs9760 (F = 5.625, p = 0.004, η2 = 0.025); GSTZ1,
rs3177429 (F = 4.820, p = 0.009, η2 = 0.022); NDUFS4
rs31304 (F = 9.757, p = 0.002, η2 = 0.022). The genotype
frequencies for each of these SNPs did not differ signifi-
cantly from Hardy-Weinberg equilibrium.
Cognitive ageing in LBC1921
Table 1 indicates the effect of each polymorphic SNP (p-
value) on each of the age 79 cognitive outcomes control-
ling for age 11 MHT score (i.e. the effect on cognitive age-
ing). Sex was included as a between subjects variable,
except in the case of PRDX4 SNP rs552105 which is on the
X chromosome. For this SNP men and women were ana-
lysed separately. Nine SNPs located in eight genes (APP,
GLRX,  HSPA9B,  MSRB2,  NDUFS1,  NDUFV2,  NDUFV3
and NOS1) showed a nominally significant association (p
< 0.01) with one of the cognitive variables (table 2). The
two SNPs in NDUFV3 were in almost complete linkage
disequilibrium. Therefore, only rs8128440 was taken for-
ward to the next stage. The minor allele frequency of SNP
rs9658446 in NOS1 was only 4.58 × 10-3, and therefore
this SNP was not carried forward to the next stage. The
genotype frequencies for each of these SNPs did not differ
significantly from Hardy-Weinberg equilibrium.
Cognitive ability and ageing in ABC1936
Nine of the 10 SNPs that showed a positive association in
LBC1921 with either age 11 cognitive ability or cognitive
ageing were successfully genotyped in ABC1936 by KBio-
sciences. The APP SNP rs2830102 was genotyped using
TaqMan® technology. None of the SNPs were significantly
associated with either age 11 MHT score or cognitive age-
ing in ABC1936 (p > 0.01). Table 3 shows the effect of
SNPs showing a positive association with at least one cog-
nitive trait at age 79 (LBC1921), controlling for sex and
age 11 cognitive ability, on cognitive traits at age 64
(ABC1936), controlling for sex and age 11 cognitive abil-
ity. The genotype frequencies for each of these SNPs did
not differ significantly from Hardy-Weinberg equilibrium.
A combined LBC1921/ABC1936 analysis to detect associations with 
cognitive ageing
Because larger sample sizes have greater power to detect
associations, general linear modelling was performed
using combined data from LBC1921 and ABC1936 to
investigate the effect of the seven SNPs that showed a sig-
nificant association with cognitive ageing in LBC1921, on
a relatively large sample size (n = 858–886). An effect size
of just 2% can be detected with > 80% power at a type-1
error rate of 0.01 using 858 subjects. The effect size of any
single polymorphism influencing variation in a complex
trait like cognitive ageing may well be relatively small, as
many polymorphisms are likely to be involved[5]. A com-
bined LBC1921/ABC1936 univariate analysis was per-
formed for the each of these seven SNP genotypes, with
later life Raven's Progressive Matrices score (the only later
life cognitive test that was measured in both cohorts) as
the dependent variable. All the cognitive tests used to
assess LBC1921 are significantly positively correlated[33]
and, therefore, associations that were previously identi-
fied with tests other than Raven score may be detected
with this test when using a larger sample size. Other
effects included in the model were age 11 MHT score, sex
and cohort (table 4). All interactions were non-significant
and removed from the models. As previously shown[31]
cohort and sex were significant for all SNP models (p <
0.001), with ABC1936 and males scoring higher than
LBC1921 and females. Age 11 MHT score contributed sig-
nificantly to later life Raven score (p < 0.001). This latter
finding reflects the highly significant partial correlation
between age 11 MHT score and later life Raven score, con-
trolling for cohort (r = 0.52, df = 892, p < 0.001). APP
intronic SNP, rs2830102, was significantly associated
with later life Raven score, controlling for age 11 MHT
score, sex and cohort (F = 5.988, p = 0.003, η2 = 0.014).
Figure 1 shows the Raven score raw data (A), and the esti-
mated marginal means (B), for later life Raven scores by
sex and cohort, controlling for age 11 MHT score. G/G
(genotype B/B in tables 2, 3 and 4) homozygotes scored
significantly lower than both heterozygotes (p = 0.029)
and A/A (genotype A/A in tables 2, 3 and 4) homozygotes
(p = 0.002). There was a trend for heterozygotes to score
lower than A/A homozygotes (p = 0.057). None of the
other SNP genotypes were significantly associated with
later life Raven score, controlling for age 11 MHT, sex and
cohort (p > 0.01).
Discussion
To our knowledge, this is the first large-scale investigation
into the possible genetic contributions to the normal var-
iability in cognitive ageing experienced by individuals. We
examined genes previously implicated in oxidative stress,
dementia and cognitive function. Of 325 gene variants
analysed, nine were positively associated with variation in
performance on one of four tests of cognitive ability at age
79 (LBC1921), controlling for sex and childhood cogni-
tive ability. Two of these SNPs were in strong linkage dis-
equilibrium and one SNP had a very low minor allele
frequency. None of these associations was replicated in a
second cohort of 64 year olds (ABC1936) who took a dif-
ferent but overlapping series of cognitive tests. Therefore,
the present study should be considered as an informative,
null study concerning a coherent set of genes that might
have, but do not, affect normal cognitive ageing, beyond
the effect size which it was powered to detect.BMC Genetics 2007, 8:43 http://www.biomedcentral.com/1471-2156/8/43
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Table 1: Effect of each polymorphic SNP on each of the cognitive outcomes, controlling for sex and age 11 cognitive ability.
Moray House
Test
Raven's Progressive
Matrices
Verbal
Fluency
Logical
Memory
Gene SNP
AGER rs3134943 .770 .808 .058 .773
rs1800684 .701 .738 .036 .773
APOD rs6786696 .982 .930 .680 .807
rs17033096 .748 .683 .527 .610
rs4686327 .580 .959 .761 .419
APP rs1787439 .817 .409 .065 .112
rs2040276 .094 .725 .108 .246
rs2026225 .736 .818 .770 .142
rs2830019 .948 .443 .809 .106
rs2830020 .948 .443 .809 .106
rs2830038 .284 .636 .076 .075
rs1041420 .022 .346 .389 .148
rs2830045 .463 .366 .398 .669
rs2830048 .247 .789 .233 .052
rs2830052 .016 .051 .932 .405
rs3787650 .669 .667 .871 .823
rs2830071 .474 .903 .469 .119
rs2830102 .003 .016 .978 .436
BACE rs535860 .994 .777 .416 .610
rs638405 .541 .184 .985 .359
CAT rs769217 .304 .804 .121 .921
CBS rs234706 .149 .299 .846 .676
CDKN1B rs3093728 .677 .767 .286 .263
rs34330 .088 .522 .413 .034
rs4251698 .632 .589 .439 .328
rs7330 .901 .782 .231 .880
CHRM2 rs8191992 associated with IQ [60]. .156 .610 .796 .781
CP rs16861582 .020 .228 .728 .318
rs1053709 .684 .682 .667 .606
rs6799507 .770 .859 .061 .854
rs701753 .576 .325 .157 .682
rs17838831 .155 .103 .786 .027
CRYAB rs4252581 .376 .683 .243 .789
rs14133 .931 .546 .696 .552
rs4252583 .097 .010 .394 .184
rs762550 .344 .713 .622 .073
CSNK1D rs6416862 .338 .506 .010 .814
CTSD rs17571 associated with AD [61] and general intelligence [62]. .355 .402 .958 .333
CTSH rs13345 .312 .964 .118 .589
rs12148472 .700 .944 .318 .406
rs1036938 .835 .509 .131 .916
CTSS rs10888390 .322 .557 .259 .127
CTSZ rs9760 .623 .387 .011 .082
DNAJB1 rs3962158 .081 .295 .216 .716
DNAJB2 rs2276638 .283 .639 .794 .321
rs3731897 .287 .546 .793 .383
FOSB rs2282695 .661 .938 .317 .762
rs2238686 .073 .036 .676 .849
FOXO3A rs12202049 .851 .557 .782 .933
rs2883881 .831 .952 .250 .098
rs17532874 .814 .848 .475 .510
rs12203787 .887 .473 .842 .892
GCLC rs1555903 .659 .336 .420 .295
GFAP rs3744473 .620 .275 .362 .674
rs3744470 .782 .716 .890 .420
rs9916491 .620 .275 .362 .674BMC Genetics 2007, 8:43 http://www.biomedcentral.com/1471-2156/8/43
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rs1126642 .669 .187 .295 .321
GLRX rs4561 .254 .560 .182 .003
GPX1 rs3448 .731 .135 .660 .464
GSR rs2251780 .232 .664 .788 .860
GSS rs6119545 .019 .029 .073 .299
rs7265992 .238 .412 .193 .619
rs2025096 .999 .897 .963 .614
GSTA2 rs6577 .683 .052 .908 .492
rs2180314 .662 .116 .395 .500
GSTA4 rs1802061 .268 .810 .365 .982
GSTA5 rs2397118 .599 .960 .763 .677
GSTM3 rs7483 .722 .926 .736 .488
GSTM4 rs560018 .747 .619 .842 .773
rs650985 .763 .756 .686 .717
GSTO1 s4925 .344 .971 .847 .119
GSTO2 rs156697 .619 .726 .405 .028
rs3758572 .670 .553 .407 .754
GSTP1 rs762803 .258 .969 .712 .688
rs947894 .206 .302 .745 .395
rs1799811 .436 .528 .110 .171
rs1871042 .269 .500 .987 .461
GSTT2 rs140188 .266 .382 .070 .297
GSTZ1 rs2270421 .072 .203 .178 .847
rs2287395 .159 .288 .174 .667
rs3177429 .245 .507 .533 .737
rs2287396 .267 .083 .884 .268
rs1046428 .312 .511 .191 .663
HMOX2 rs6500610 .635 .364 .275 .215
rs11643057 .733 .411 .666 .363
rs17137094 .010 .011 .189 .675
HSPA12A rs1665659 .443 .454 .067 .362
rs4752003 .030 .010 .619 .689
rs1665638 .783 .645 .270 .293
rs740599 .585 .630 .865 .758
rs1900501 .247 .025 .435 .190
HSPA12B rs3827077 .121 .689 .473 .190
rs6076550 .493 .505 .828 .870
rs2295340 .516 .725 .462 .612
HSPA1L rs2075800 .133 .371 .267 .845
HSPA2 rs17101915 .493 .583 .051 .249
rs11848114 .251 .615 .109 .110
HSPA4 rs398606 .680 .021 .216 .775
rs14355 .096 .062 .716 .246
HSPA5 rs430397 .348 .413 .084 .825
HSPA8 rs3763897 .349 .020 .119 .960
HSPA9B rs10117 .006 .211 .261 .267
HTR2A rs3803189 .128 .118 .984 .910
rs6314 associated with episodic memory [63]. .096 .180 .429 .388
rs1923884 .966 .601 .948 .773
rs6305 .151 .746 .926 .133
rs6313 associated with AD [64]. .209 .079 .996 .885
IDE rs7895832 .181 .093 .690 .470
rs3758505 associated with AD [65]. .181 .093 .690 .470
IL1B rs1143634 associated with AD [66]. .372 .082 .738 .450
rs16062 .508 .404 .711 .484
rs1143627 .591 .872 .354 .926
LTF rs4683233 .220 .073 .826 .023
MPO rs2759 .500 .154 .634 .301
rs7208693 .959 .940 .782 .945
MSRA rs12679328 .950 .072 .466 .063
rs3735823 .985 .087 .833 .245
rs814422 .237 .111 .462 .584
rs1994224 .460 .078 .592 .414
Table 1: Effect of each polymorphic SNP on each of the cognitive outcomes, controlling for sex and age 11 cognitive ability. (Continued)BMC Genetics 2007, 8:43 http://www.biomedcentral.com/1471-2156/8/43
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rs6601414 .034 .386 .211 .717
rs17151140 .396 .191 .876 .567
rs1484645 .609 .343 .252 .039
rs6986977 .510 .907 .764 .261
rs877390 .661 .389 .544 .690
rs7845503 .437 .936 .722 .020
rs6992349 .956 .718 .292 .573
rs4288376 .189 .373 .503 .250
rs10503405 .965 .353 .263 .871
rs6983870 .271 .246 .432 .265
rs4260895 .263 .069 .341 .154
rs2952182 .355 .612 .586 .832
rs11783821 .437 .523 .149 .586
rs17151588 .204 .360 .309 .214
rs7832708 .233 .151 .899 .021
rs4841322 .746 .663 .882 .400
rs4841324 .706 .644 .849 .435
MSRB2 rs10764383 .951 .540 .043 .272
rs11013295 .862 .668 .404 .354
rs7427 .006 .111 .487 .550
NDRG1 rs2977499 .536 .626 .436 .829
rs2272653 .970 .517 .812 .184
rs2930002 .961 .599 .502 .543
NDUFA10 rs2083411 .594 .085 .809 .255
NDUFA3 rs254259 .021 .020 .517 .269
NDUFA6 rs1801311 .630 .207 .074 .036
NDUFA7 rs561 .417 .734 .077 .754
rs2241591 .239 .180 .366 .774
NDUFA8 rs4147659 .180 .585 .584 .574
rs6822 .238 .634 .690 .646
rs4679 .079 .592 .405 .389
NDUFA9 rs4147672 .611 .387 .825 .723
rs4147682 .611 .387 .825 .723
NDUFAB1 rs459894 .620 .580 .948 .070
NDUFAF1 rs3204853 .294 .162 .506 .566
NDUFB10 rs2302175 .129 .533 .878 .373
NDUFB5 rs2339844 .590 .320 .894 .083
NDUFB7 rs9543 .676 .552 .081 .032
NDUFB8 rs1800662 .354 .447 .709 .738
NDUFB9 rs11547284 .483 .023 .690 .840
NDUFS1 rs11548670 .166 .258 .002 .287
rs4147707 .977 .610 .613 .993
NDUFS2 rs3813624 .225 .973 .255 .783
rs16832694 .490 .890 .878 .229
rs16832699 .225 .973 .255 .783
rs11587213 .957 .200 .293 .925
NDUFS4 rs4147732 .727 .369 .422 .516
rs2279516 .710 .876 .073 .240
rs13156337 .417 .608 .468 .075
rs31304 .451 .409 .938 .341
rs31303 .783 .260 .609 .885
rs567 .688 .190 .226 .641
NDUFS6 rs3776141 .329 .561 .117 .011
NDUFV2 rs906807 .346 .009 .892 .732
NDUFV3 rs4148973 .718 .473 .0003 .559
rs8128440 .710 .500 .0002 .742
NOS1 rs9658501 .278 .275 .696 .799
rs3741475 .556 .447 .469 .212
rs10774909 .393 .138 .533 .338
rs9658446 .062 .186 .249 .004
rs2293054 .443 .289 .893 .718
rs11612772 .659 .255 .253 .737
rs561712 .795 .719 .870 .628
Table 1: Effect of each polymorphic SNP on each of the cognitive outcomes, controlling for sex and age 11 cognitive ability. (Continued)BMC Genetics 2007, 8:43 http://www.biomedcentral.com/1471-2156/8/43
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rs9658256 .661 .270 .405 .089
NOS2A rs2297512 .187 .471 .553 .164
rs2297518 .504 .285 .556 .254
rs1137933 .455 .429 .206 .428
rs3730017 .318 .955 .342 .373
NOS3 rs1549758 .179 .489 .620 .463
rs1799983 associated with mild cognitive impairment [67]. .380 .263 .779 .258
rs2566514 .738 .774 .876 .298
rs3918232 .612 .092 .226 .546
NR2C2 rs17536979 .480 .367 .719 .206
rs648912 .957 .489 .849 .358
PLAU rs2227564 associated with AD [68]. .766 .877 .796 .623
rs2227567 .121 .816 .508 .440
rs2227568 .974 .696 .053 .886
rs4065 .459 .953 .120 .293
PON2 rs6954345 .054 .261 .510 .788
rs10487133 .294 .661 .510 .686
rs11545941 .054 .261 .510 .788
rs17166875 .054 .261 .510 .788
PRDX1 rs6667191 .912 .697 .763 .689
PRDX2 rs10413408 .824 .251 .445 .773
rs10422248 .824 .251 .445 .773
PRDX4* rs552105 (male) .611 .942 .495 .509
rs552105 (female) .856 .569 .894 .898
rs1548734 (male) .611 .942 .495 .509
rs1548734 (female) .832 .515 .891 .870
SAA2 rs2468844 .558 .557 .676 .596
SEPP1 rs6413428 .073 .055 .948 .307
rs7579 .616 .677 .851 .786
SIRT1 rs2273773 .967 .517 .358 .730
rs2234975 .937 .840 .454 .750
SLC25A27 rs9369628 .383 .213 .990 .646
rs12192544 .881 .251 .989 .739
rs3757241 .126 .975 .304 .739
SOD2 rs1799725 .381 .937 .438 .111
SOD3 rs1799895 .485 .813 .745 .924
TF rs1130459 .153 .069 .260 .311
rs1799852 .685 .237 .149 .919
rs1799899 .789 .722 .454 .835
rs1049296 .434 .899 .829 .621
rs3811656 .087 .025 .248 .796
TXN rs4135162 .157 .747 .929 .289
TXN2 rs2281082 .951 .220 .864 .253
TXNRD1 rs11111979 .755 .026 .399 .709
rs7134193 .850 .101 .314 .737
rs4964287 .924 .205 .035 .615
TXNRD2 rs3827288 .585 .211 .136 .471
rs5992495 .879 .865 .209 .056
rs5748469 .577 .780 .232 .832
rs5746847 .388 .983 .125 .691
TXNRD3 rs777241 .993 .767 .270 .498
UCP2 rs660339 .578 .723 .520 .372
VEGF rs2010963 .980 .766 .372 .228
rs833068 .974 .765 .434 .205
rs3025000 .849 .828 .408 .227
rs3025010 .192 .935 .267 .161
rs3025039 .112 .130 .882 .230
rs3025053 .487 .326 .705 .620
VIM rs1049341 .336 .976 .815 .887
p values are given. p values < 0.01 are in bold. SNPs previously associated with intelligence or AD are indicated.
*PRDX4 is located on the X chromosome and therefore men and women were analyzed separately.
Table 1: Effect of each polymorphic SNP on each of the cognitive outcomes, controlling for sex and age 11 cognitive ability. (Continued)BMC Genetics 2007, 8:43 http://www.biomedcentral.com/1471-2156/8/43
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However,  APP  intronic SNP rs2830102 genotype was
associated with non-verbal reasoning, as measured by
Raven's Progressive Matrices, in a joint analysis of
LBC1921 and ABC1936 data. It is emphasised, though,
that it did not have significant effects in both cohorts sep-
arately, and as such it needs replicating in other cohorts.
APP genotype accounted for 1.4% of the variance in the
Raven scores, after adjustment for sex, cohort and child-
hood ability differences. Although this is a relatively small
effect size, it is what is expected with a complex trait like
cognitive ageing, where many variants are likely to be
involved. APOE, which is one of the few genes that has
been associated with cognitive ageing in several cohorts,
including LBC1921[7], has an effect size of just 1% to 2%
and is considered to be important. 12.4% of the variance
was accounted for by the cohort of the participants.
ABC1936 participants who, at age 64, were 15 years
younger, scored significantly better than the 79-year-olds
in the LBC1921 (p < 0.001). No significant interaction
between year of cohort and APP genotype was identified.
APP encodes the amyloid β (Aβ) precursor protein. Extra-
cellular Aβ plaques, which form in the meningeal vessels
of AD patient brains, are a defining feature of the disease.
Mutations in both the coding region[34] and the pro-
moter region[35] of this gene have been associated with
AD. Aberrant expression of APP has also been implicated
in AD[36,37]. AD is characterised by an impairment of
multiple cognitive domains. Amyloidogenic peptide
derivatives of mutant APP have been implicated in the
generation of free radicals and with mitochondrial oxida-
tive damage (reviewed in[38]). It is possible that common
variation in APP DNA sequence is associated with varia-
tion in oxidative stress in the general population, leading
to variation in normal cognitive ageing. This may reflect
the possibility that the neurobiology of both cognitive
ageing and AD is, to some extent, a continuum. It is also
possible that the association between APP SNP rs2830102
and normal cognitive ageing, as measured using Raven's
Progressive Matrices, is related to incipient AD in some
members of LBC1921 and ABC1936.
Table 2: SNPs showing a significant (p < 0.01) association with at least one cognitive trait at age 79 (LBC1921), controlling for sex and 
age 11 cognitive ability.
No. of subjects
with each genotype
Moray House Test Raven's Progressive
Matrices
Verbal Fluency Logical Memory
Gene SNP A/A A/B B/B F p η2 F p η2 F p η2 F p η2
APP rs2830102 46 177 214 5.835 .003 .026 4.163 .016 .019 .023 .978 .000 .831 .436 .004
GLRX rs4561 160 222 54 1.375 .254 .006 .580 .560 .003 1.712 .182 .008 5.893 .003 .027
HSPA9B rs10117 66 217 154 5.194 .006 .024 1.563 .211 .007 1.349 .261 .006 1.326 .267 .006
MSRB2 rs7427 53 200 184 5.099 .006 .023 2.212 .111 .010 .722 .487 .003 .598 .550 .003
NDUFS1 rs11548670 412 25 0 1.922 .166 .004 1.281 .258 .003 9.629 .002 .022 1.135 .287 .003
NDUFV2 rs906807 17 134 286 1.063 .346 .005 4.733 .009 .022 .114 .892 .001 .312 .732 .001
NDUFV3 rs4148973 54 196 187 .332 .718 .002 .749 .473 .003 8.379 .0003 .038 .583 .559 .003
NDUFV3 rs8128440 186 195 55 .342 .710 .002 .694 .500 .003 8.816 .0002 .039 .299 .742 .001
NOS1 rs9658446 0 4 433 3.491 .062 .008 1.754 .186 .004 1.334 .249 .003 8.567 .004 .019
p values < 0.01 are highlighted in bold.
Table 3: Effect of SNPs showing a significant (p < 0.01) association with at least one cognitive trait at age 79 (LBC1921), controlling for 
sex and age 11 cognitive ability, on cognitive traits at age 64 (ABC1936), controlling for sex and age 11 cognitive ability.
No. of subjects with each genotype BD DS RM UCO AVLT
Gene SNP A/A A/B B/B
APP rs2830102 29 168 167 .380 .855 .345 .167 .984
GLRX rs4561 128 171 66 .465 .426 .391 .044 .848
HSPA9B rs10117 56 180 142 .433 .963 .012 .841 .698
MSRB2 rs7427 41 164 174 .451 .585 .813 .484 .650
NDUFS1 rs11548670 351 25 1 .570 .113 .956 .395 .144
NDUFV2 rs906807 11 102 256 .953 .749 .783 .410 .672
NDUFV3 rs8128440 145 178 41 .856 .903 .509 .146 .515
p values are given.
Key: BD = Block Design, DS = Digit Symbol, RM = Raven's Progressive Matrices, UCO = Use of Common Objects, AVLT = Auditory Verbal 
Learning TestBMC Genetics 2007, 8:43 http://www.biomedcentral.com/1471-2156/8/43
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SNP rs2830102 is located in intron 1 of APP and may
affect regulation of gene expression. Although the SNP
does not lie in a predicted promoter region[39] and is not
predicted to alter splicing it does occur within a region of
sequence conservation[40]. Alternatively it may be in
linkage disequilibrium with another functional SNP, pos-
sibly in the promoter of the gene. It is important that the
APP gene is investigated further for its role in both non-
pathological cognitive ageing and AD.
Several of the SNPs investigated in this study had previ-
ously been associated with intelligence or AD (table 1).
We failed to find any significant association between these
SNPs and either cognitive ability at age 11 or cognitive
ageing in LBC1921. Such attempted replications are
important, because initial reports of genotype-phenotype
associations often do not replicate.
To investigate genetic influences on non-pathological cog-
nitive ageing we chose to perform a relatively large scale
genetic association study using candidate genes, for which
there was strong a priori evidence for their involvement in
brain ageing. We focussed on a specific ageing-related
mechanism, that of oxidative stress. We were in the inval-
uable position of being able to test directly for cognitive
ageing across a long period of time, as we had cognitive
ability scores at both age 11 and in later life. There has
been much discussion in the literature regarding larger
scale association study designs. We chose a candidate
genes approach that allowed the use of smaller numbers
of SNPs compared to a whole genome association study.
However, it is likely that important regions of the genome
were missed by this approach. We followed recent guide-
lines from a genomewide association scan workshop[41]
that concluded that multistage designs, whereby a sub-set
of subjects are initially genotyped and additional subjects
are then genotyped for SNPs that show a positive associa-
tion, enhanced the efficiency of such studies. We chose to
genotype a limited number of potentially functional SNPs
in a larger number of genes rather than to attempt to fully
cover a smaller number of genes using, for example, tag-
ging SNPs and may therefore have missed important SNPs
whose functionality was not predicted. We considered this
a more efficient use of limited genotyping funds. It
allowed us to cover more of our candidate genes and
increased the likelihood that we would identify a causa-
tive SNP, particularly as concern exists over the portability
of tagging SNPs across populations. A few recent prelimi-
nary studies indicate that it may be possible to use tagging
SNPs designed in one population to investigate associa-
tions in a second population, but this should only be
done with caution [42-45]. With regard to the analysis, we
decided to initially concentrate on the identification of
individual SNPs that have a detectable main effect on var-
iation in cognitive ageing. However, in the future we may
include newly developed statistical techniques that allow
the identification of interlocus interactions[46].
Like all large scale genetic association studies, this study
suffers from the problem of multiple testing; we initially
investigated 325 SNPs and four cognitive tests in 437 sub-
jects. Because many of the SNPs are in linkage disequilib-
rium and, moreover, scores on the cognitive tests are
positively correlated, it was deemed inappropriate to per-
form a Bonferroni-type correction. However, we were able
to genotype SNPs showing a nominally significant associ-
ation in the first cohort, with a second equally large and
valuable cohort and, we used a relatively stringent p val-
ueof < 0.01.
It is also important, given the relatively small size and
younger age of the replication cohort (n = 485), that SNPs
that showed a positive association in LBC1921, but not in
ABC1936 or the combined cohorts, are investigated in
future association studies to identify genetic determinants
of cognitive ageing. A further caveat of the study is that
ABC1936 did not take exactly the same cognitive tests as
LBC1921. Therefore, associations identified in LBC1921
Table 4: Effect of SNPs showing a significant (p < 0.01) association with at least one cognitive trait at age 79 (LBC1921), controlling for 
sex and age 11 cognitive ability, on Raven's Progressive Matrices Score in later life controlling for sex, age 11 cognitive ability and 
cohort (ABC1936 or LBC1921).
No. of subjects with each genotype Raven's Progressive Matrices
Gene SNP A/A A/B B/B F p η2
APP rs2830102 79 381 415 5.988 .003 .014
GLRX rs4561 323 424 127 .846 .429 .002
HSPA9B rs10117 133 433 323 1.528 .217 .003
MSRB2 rs7427 106 396 386 1.443 .237 .003
NDUFS1 rs11548670 829 56 1 .533 .587 .001
NDUFV2 rs906807 30 252 595 3.625 .027 .008
NDUFV3 rs8128440 353 414 104 .736 .479 .002
p values < 0.01 are highlighted in bold.BMC Genetics 2007, 8:43 http://www.biomedcentral.com/1471-2156/8/43
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Score on Raven's Matrices by APP rs2830102 genotype, sex and cohort (LBC1921 or ABC1936): A) raw data; B) estimated  marginal means from general linear model, adjusted for age 11 MHT score Figure 1
Score on Raven's Matrices by APP rs2830102 genotype, sex and cohort (LBC1921 or ABC1936): A) raw data; B) estimated 
marginal means from general linear model, adjusted for age 11 MHT score.
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may have been with specific cognitive abilities that were
not examined in ABC1936.
Conclusion
This study has identified a number of genes, for which
there was strong a priori evidence for their involvement in
cognitive ageing, which have an association with cogni-
tive ageing in a cohort of relatively healthy 79 year old
subjects (LBC1921). A significant association with a SNP
in the gene encoding APP was also identified in a com-
bined analysis of LBC1921 and a second younger cohort
(ABC1936), suggesting its importance in cognitive ageing
as well as AD. It is important that the role of this gene in
cognitive ageing is investigated further.
Methods
Subjects
The subjects recruited to this study originally participated,
at the age of about 11 years, in the Scottish Mental Surveys
of either 1932 or 1947[32,47,48]. On June 1st 1932 and
June 4th 1947 a valid mental ability test, a version of the
Moray House Test No. 12 (MHT), was given to almost all
Scottish children attending school on the Survey day who
were born in 1921 (N = 87,498) or 1936 (N = 70,805),
respectively.
Lothian Birth Cohort 1921 (LBC1921)
LBC1921 are surviving participants of the Scottish Mental
Survey of 1932, who were living independently in the
Edinburgh area at the time of recruitment. Further testing
and recruitment details have been published previ-
ously[32]. Mean age at re-test was 79.1 years (SD = 0.6
years), and all subjects were Caucasian. The following
inclusion criteria were applied: Cognitive ability scores
were available at age 11 and age 79; there was no history
of dementia; Mini-Mental State Examination (MMSE)
score was 24 or greater; and SNP genotyping was success-
ful. This gave a total of 437 subjects (261 women, 176
men).
Aberdeen Birth Cohort 1936 (ABC1936)
ABC1936 are surviving participants of the Scottish Mental
Survey of 1947, who were living independently in the city
of Aberdeen at the time of recruitment. Further recruit-
ment details have been published previously[49,50].
Mean age at re-test was 64.6 years (SD = 0.7 years), and all
subjects were Caucasian. The following inclusion criteria
were applied: Cognitive ability scores were available at age
11 and age 64 and Mini-Mental State Examination
(MMSE) score was 24 or greater. This gave a total of 485
subjects (246 women, 239 men).
Cognitive testing
Moray House Test No. 1(MHT)
All subjects took this general mental ability test at age 11,
in the Scottish Mental Surveys of 1932 and 1947.
LBC1921 re-took the test at about age 79. The test is
described fully elsewhere[1,32,47]. The same instructions
and the time limit (45 minutes) were used on both occa-
sions. At re-test, ABC1936 took subtests of the Wechsler
Adult Intelligence Scale-Revised instead of the MHT[51]:
the Block Design, which measures visuo-spatial ability,
and Digit Symbol, which measures speed of information
processing[51].
Mini-Mental State Examination (MMSE)
MMSE[52] was used to screen both cohorts for possible
dementia. Maximum score is 30. A score of less than 24
was used here as an exclusion criterion because it is often
adopted as an indicator of possible dementia.
Both cohorts underwent a series of mental tests designed
to examine different cognitive functions: non-verbal rea-
soning, executive function, and memory and learning. We
have previously described this testing in detail[32,53].
The individual cognitive functions of the two independ-
ent cohorts (LBC1921 and ABC1936) were examined
using a different series of tests as indicated below:
Non-verbal reasoning
Raven's Progressive Matrices[54]
Non-verbal reasoning was examined in all subjects using
Raven's Standard Progressive Matrices. The time limit was
20 minutes.
Executive Function
Verbal fluency
LBC1921 took the verbal fluency test, which is described
as a test of prefrontal executive function[55,56].
Uses of Common Objects
ABC1936 took the use of common objects test, which is
described as a test of executive function or purposive
action[55].
Verbal Memory and Learning
Logical Memory
LBC1921 took the Logical Memory test, which is a verbal
declarative memory sub-test from Wechsler Memory
Scale-Revised[57].
Rey Auditory Verbal Learning Test
ABC1936 took the auditory verbal learning test which
assesses short and longer term memory and learning[55].BMC Genetics 2007, 8:43 http://www.biomedcentral.com/1471-2156/8/43
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Illumina SNP selection
A list of 141 brain-expressed genes was selected and pro-
vided to Illumina (table 5). They were selected if they
were: a) implicated in antioxidant defence; b) vitagenes
(longevity assurance processes); c) associated with cogni-
tive function; d) associated with AD; e) "stress response"
genes showing an increased expression in the aged mouse
[28]; and/or f) nuclear genes encoding mitochondrial
complex 1 proteins. From an initial list of 14,033 poten-
tial SNPs, 384 were selected for genotyping using the fol-
lowing criteria: a) all designable (including designability
score 0.5) SNPs previously associated with AD and cogni-
tive function; b) all designable (including designability
score 0.5) functional SNPs; c) all non-synonymous vali-
dated and designable (including designability score 0.5)
SNPs; d) all validated and designable (including designa-
bility score 0.5) SNPs at exon/intron boundaries that
potentially alter splicing; e) all validated and designable
(including designability score 0.5) SNPs with percentage
identity in mouse >= 80%; f) all validated and designable
(excluding designability score 0.5) SNPs with percentage
identity in mouse between 60% and 80%; g) remaining
SNPs were Illumina validated synonymous SNPs in previ-
ously unrepresented genes (see additional file 1). Design-
ability is ranked as 0, 0.5 or 1. A "0" is assigned to SNPs
for which an assay cannot be designed, "0.5" indicates the
SNP has a designability score low enough to suggest that
there might be challenges to the design, and "1" is
reserved for those that do not appear to have any chal-
lenges in their designability. Validation class is ranked as
1, 2, or 3. "1" means that a SNP is nonvalidated, "2" is a
two-hit SNP (non Illumina validated, i.e. it has been vali-
dated on some other platform on more than one chromo-
some), and "3" means two-hit Illumina validated. The
percentage identity with mouse is based on a 120 base
pair window surrounding the SNP.
Genotyping of LBC1921
Genomic DNA was extracted from blood using standard
methods. Genotyping of 384 SNPs was performed using
the GoldenGate™ assay by the Illumina BeadLab service
facility in San Diego. 444 LBC1921 subjects were geno-
typed, 16 of them in duplicate. A further three SNPs
(MPO, rs7208693; TF, rs3811656 and NDUFAF1
rs3204853) were genotyped at the Welcome Trust Clinical
Research Facility Genetics Core, Western General Hospi-
tal, Edinburgh[58] using TaqMan® technology (Applied
Biosystems).
Genotyping of ABC1936
Genomic DNA was extracted from blood using standard
methods. Genotyping in LBC1921 found seven independ-
ent SNPs significantly associated with cognitive ageing (p
< 0.01), and three SNPs significantly associated with age
11 MHT score. Genotyping for these SNPs was attempted
in ABC1936, using KASPar, by Kbiosciences (Herts, UK).
In cases where a KBiosciences assay could not be designed,
genotyping was performed at the Welcome Trust Clinical
Research Facility Genetics Core, Western General Hospi-
tal, Edinburgh[58] using TaqMan® technology.
Statistical analysis
The power to detect a causative variant at a type-1 error
rate of 0.01, for a variant explaining 2–3% of the variance,
was estimated by calculating the non-centrality parameter
of a non-central χ2 and the probability that the test statis-
tic under the alternative hypothesis would be larger than
the threshold corresponding to the specified type-1
error[59].
The effect of each SNP genotype on LBC1921 age 11 MHT
score was analysed using general linear modelling (uni-
variate analysis of variance). The fixed effects (between
subjects variables) were: SNP genotype and sex.
The effect of each SNP genotype on each of the four age 79
cognitive outcome variables, for LBC1921, was analysed
using general linear modelling (multivariate analysis of
variance). The fixed effects were: SNP genotype and sex.
Age 11 MHT score was included as a covariate, allowing us
to identify associations specifically with cognitive ageing.
General linear modelling, as described above, was used to
identify associations between SNPs that showed a positive
association in LBC1921 (with either age 11 MHT score or
cognitive ageing), and age 11 MHT score and each of the
five age 64 cognitive outcome variables (controlling for
age 11 MHT score), for ABC1936.
The raw data from LBC1921 and ABC1936 were com-
bined and the effect of each SNP on the Raven's Progres-
sive Matrices Score was analysed using general linear
modelling (univariate analysis of variance). In addition to
SNP genotype and sex, cohort was added to the model as
a fixed effect and age 11 MHT score was included as a cov-
ariate.
All general linear modelling was performed using SPSS
v12.0. Statistical significance was set at p < 0.01 for all sta-
tistical tests.
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Table 5: Cognitive Ageing Candidate Genes (expressed in the brain).
gene symbol gene name and function
antioxidant defence genes
BACE1 beta-site APP-cleaving enzyme 1. Responsible for the proteolytic processing of the amyloid precursor protein 
(APP).
CAT catalase. Protects cells from the toxic effects of hydrogen peroxide. Contains functional promoter polymorphism 
[69].
CBS cystathionine-beta-synthase.
CCS copper chaperone for SOD. Delivers Cu/Zn to SOD1
CDKN1B cyclin-dependent kinase inhibitor 1B (p27, Kip1). Involved in G1 arrest.
CP ceruloplasmin. Ceruloplasmin is a blue, copper-binding (6–7 atoms per molecule) glycoprotein found in plasma. 
Four possible functions are ferroxidase activity, amine oxidase activity, copper transport and homeostasis, and 
superoxide dismutase activity.
FOXO3A forkhead transcription factor (homologue of C elegans daf-16). May trigger apoptosis.
FTH1 ferritin, heavy polypeptide 1. Ferritin is an intracellular molecule that stores iron in a soluble, nontoxic, readily 
available form.
FTL ferritin light polypeptide.
FXN frataxin. Defects in FXN are the cause of Friedreich's ataxia. Probably involved in iron homeostasis.
GCLC glutamate-cysteine ligase, catalytic subunit. The first rate-limiting enzyme in glutathione biosynthesis.
GGT1 gamma-glutamyltransferase 1. Initiates extracellular gluthatione (GSH) breakdown, provides cells with a local 
cysteine supply and contributes to maintain intracelular GSH level.
GLRX glutaredoxin (thioltransferase). GLRX has a glutathione-disulfide oxidoreductase activity in the presence of 
NADPH and glutathione reductase. Reduces low molecular weight disulfides and proteins.
GLRX2 glutaredoxin 2 (mitochondrial). Catalyses the reversible oxidation and glutathionylation of mitochondrial 
membrane thiol proteins. Implicated in the protection of mitochondria from ROS.
GPX1 glutathione peroxidase 1 (cytosolic). GPX catalyzes the reduction of hydrogen peroxide, organic hydroperoxide, 
and lipid peroxides by reduced glutathione and functions in the protection of cells against oxidative damage. 
Selinium in the form of selenocysteine is part of its catalytic site. GPX1 protects the hemoglobin in erythrocytes 
from oxidative breakdown. Can be targetted to mitochondria
GPX3 glutathione peroxidase 3 (plasma).
GPX4 glutathione peroxidase 4 (membrane associated phospholipid hydroperoxide GPX). Could play a major role in 
protecting mammals from the toxicity of ingested lipid hydroperoxides. Essential for embryonic development. Can 
be targetted to the mitochondria.
GSR glutathione reductase. Maintains high levels of reduced glutathione in the cytosol.
GSS glutathione synthetase. The second rate-limiting enzyme in glutathione biosynthesis.
GSTA1 glutathione S-transferase A1. GSTs are a family of phase II enzymes that utilize glutathione in reactions contributing 
to the transformation of a wide range of exogenous and endogenous compounds, including carcinogens, 
therapeutic drugs, and products of oxidative stress.
GSTA2 glutathione S-transferase A2.
GSTA3 glutathione S-transferase A3.
GSTA4 glutathione S-transferase A4.
GSTA5 glutathione S-transferase A5.
GSTK1 glutathione S-transferase kappa 1.
GSTM1 glutathione S-transferase M1.
GSTM3 glutathione S-transferase M3 (brain).
GSTM4 glutathione S-transferase M4.
GSTM5 glutathione S-transferase M5.
GSTO1 glutathione S-transferase omega 1. GSTO1 exhibits glutathione-dependent thiol transferase and dehydroascorbate 
reductase activities. May have a significant housekeeping function, such as protection from oxidative stress.
GSTO2 glutathione S-transferase omega 2.
GSTP1 glutathione S-transferase pi.
GSTT1 glutathione S-transferase theta 1.
GSTT2 glutathione S-transferase theta 2.
GSTZ1 glutathione transferase zeta 1 (maleylacetoacetate isomerase).
LTF lactotransferrin.
MPO myeloperoxidase. Part of the host defence system of polymorphonuclear leukocytes. It is responsible for 
microbicidal activity against a wide range of organisms. In the stimulated PMN, MPO catalyzes the production of 
hypohalous acids, primarily hypochlorous acid in physiologic situations, and other toxic intermediates that greatly 
enhance PMN microbicidal activity.
MSRA methionine sulfoxide reductase A. Has an important function as a repair enzyme for proteins that have been 
inactivated by oxidation. Catalyzes the reversible oxidation-reduction of methionine sulfoxide in proteins to 
methionine.BMC Genetics 2007, 8:43 http://www.biomedcentral.com/1471-2156/8/43
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MSRB methionine sulfoxide reductase B.
NOS1 nitric oxide synthase 1 (neuronal) (mtNOS). Produces nitric oxide (NO) a free radical messenger molecule. NO 
regulates mitochondrial respiration.
NOS2A nitric oxide synthase 2A (inducible, hepatocytes).
NOS2B nitric oxide synthase 2B.
NOS2C nitric oxide synthase 2C.
NOS3 nitric oxide synthase 3 (endothelial cell). Polymorphism associated with mild cognitive impairment [67].
PON2 paraoxonase 2. Hydrolyzes the toxic metabolites of a variety of organophosphorus insecticides. Capable of 
hydrolyzing a broad spectrum of organophosphate substrates and a number of aromatic carboxylic acid esters (By 
similarity). Has antioxidant activity. Is not associated with high density lipoprotein. Prevents LDL lipid peroxidation, 
reverses the oxidation of mildly oxidized LDL, and inhibits the ability of MM-LDL to induce monocyte chemotaxis.
PRDX1 peroxiredoxin 1. PRDX (a thioredoxin peroxidase) reduces hydrogen peroxide and alkyl hydroperoxide to water 
and alcohol respectively. Involved in redox regulation of the cell. Reduces peroxides with reducing equivalents 
provided through the thioredoxin system but not from glutaredoxin. May play an important role in eliminating 
peroxides generated during metabolism. Might participate in the signaling cascades of growth factors and tumor 
necrosis factor-alpha by regulating the intracellular concentrations of H(2)O(2).
PRDX2 peroxiredoxin 2.
PRDX3 peroxiredoxin 3 (mitochondrial).
PRDX4 peroxiredoxin 4.
PRDX5 peroxiredoxin 5 (mitochondrial, peroxisomal and cytoplasmic).
PRDX6 peroxiredoxin 6. PRDX6 mutant mice are susceptible to oxidative stress.
SEPP1 selenoprotein P, plasma, 1. Might be responsible for some of the extracellular antioxidant defence properties of 
selenium or might be involved in the transport of selenium. May supply selenium to tissues such as brain and testis.
SIRT1 sirtuin (silent mating type information regulation 2 homolog) 1 (S. cerevisiae) controls the cellular response to 
stress by regulating the FOXO family. SIRT1 and FOXO3 form a complex in cells in response to oxidative stress.
SLC25A27 solute carrier family 25, member 27. (UCP4)
SOD1 superoxide dismutase 1 (cytoplasmic). SOD catalyses the formation of hydrogen peroxide and oxygen from 
superoxide, and thus protects against superoxide-induced damage.
SOD2 superoxide dismutase 2 (mitochondria)
SOD3 superoxide dismutase 3 (extracellular)
TF transferrin. Transferrins are iron binding transport proteins which can bind two atoms of ferric iron in association 
with the binding of an anion, usually bicarbonate. It is responsible for the transport of iron from sites of absorption 
and heme degradation to those of storage and utilization. Serum transferrin may also have a further role in 
stimulating cell proliferation.
TXN thioredoxin. Participates in various redox reactions through the reversible oxidation of its active center dithiol to 
a disulfide and catalyzes dithiol-disulfide exchange reactions.
TXN2 thioredoxin 2 (mitochondrial). A mitochondrial protein-disulphide oxidoreductase essential for control of cell 
survival during mammalian embryonic development.
TXNRD1 thioredoxin reductase 1.
TXNRD2 thioredoxin reductase 2 (mitochondrial). Maintains thioredoxin in a reduced state. Implicated in the defences 
against oxidative stress.
TXNRD3 thioredoxin reductase 3.
UCP2 uncoupling protein 2 (mitochondrial, proton carrier). UCP are mitochondrial transporter proteins that create 
proton leaks across the inner mitochondrial membrane, thus uncoupling oxidative phosphorylation from ATP 
synthesis. As a result, energy is dissipated in the form of heat.
Vitagenes (longevity 
assurance processes-
chaperones)
HMOX1 heme oxygenase (decycling) 1(HSP32) (stress induced). Heme oxygenase cleaves the heme ring at the alpha 
methene bridge to form biliverdin. Biliverdin is subsequently converted to bilirubin (an antioxidant) by biliverdin 
reductase.
HMOX2 heme oxygenase (decycling) 2 (constitutive).
HSPA1A heat shock 70 kDa protein 1A. Member of the HSP70 family. HSP70s stabilize preexistent proteins against 
aggregation and mediate the folding of newly translated polypeptides in the cytosol as well as within organelles. The 
HSP70s in mitochondria and the endoplasmic reticulum play an additional role by providing a driving force for 
protein translocation. They are involved in signal transduction pathways in cooperation with HSP90. They 
participate in all these processes through their ability to recognize nonnative conformations of other proteins. 
They bind extended peptide segments with a net hydrophobic character exposed by polypeptides during 
translation and membrane translocation, or following stress-induced damage.
HSPA1B heat shock 70 kDa protein 1B.
HSPA1L heat shock 70 kDa protein 1-like.
HSPA2 heat shock 70 kDa protein 2.
HSPA4 heat shock 70 kDa protein 4.
HSPA5 heat shock 70 kDa protein 5 (glucose-regulated protein, 78 kDa).
HSPA6 heat shock 70 kDa protein 6 (HSP70B').
Table 5: Cognitive Ageing Candidate Genes (expressed in the brain). (Continued)BMC Genetics 2007, 8:43 http://www.biomedcentral.com/1471-2156/8/43
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HSPA8 heat shock 70 kDa protein 8. Polymorphism associated with mild mental impairement [70].
HSPA9B heat shock 70 kDa protein 9B (mortalin-2). Implicated in the control of cell proliferation and cellular aging. May 
also act as a chaperone.
HSPA12A heat shock 70 kDa protein 12A.
HSPA12B heat shock 70 kD protein 12B.
HSPA14 heat shock 70 kDa protein 14.
genes associated with 
cognitive function
AR androgen receptor. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene 
expression and affect cellular proliferation and differentiation in target tissues. CAG repeat polymorphism is 
associated with cognitive function in older men [71].
CHRM2 cholinergic muscarinic 2 receptor. The muscarinic acetylcholine receptor mediates various cellular responses, 
including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels 
through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Polymorphism 
associated with IQ [60].
CTSD cathepsin D (lysosomal aspartyl protease). Acid protease active in intracellular protein breakdown. Polymorphism 
associated with AD [61] and general intelligence in a healthy older population [62].
VEGF vascular endothelial growth factor. Growth factor active in angiogenesis, vasculogenesis and endothelial cell 
growth. VEGF links hippocampal activity with neurogenesis, learning and memory [72].
genes associated with AD
AGER advanced glycosylation end product-specific receptor (RAGE). Mediates interactions of advanced glycosylation end 
products (AGE). Increased expression in AD [73].
APP amyloid beta (A4) precursor protein. Polymorphisms associated with AD (reviewed in [34]).
HTR2A 5-hydroxytryptamine (serotonin) receptor 2A. This is one of the several different receptors for 5-
hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a 
mitogen. Polymorphisms associated with episodic memory [63,74] and neuropsychiatric symptoms in AD [64].
IDE insulin degrading enzyme. May play a role in the cellular processing of insulin. May be involved in intercellular 
peptide signaling. Polymorphism associated with AD [65].
IL1B interleukin 1, beta. Produced by activated macrophages. IL-1 proteins are involved in the inflammatory response, 
being identified as endogenous pyrogens, and are reported to stimulate the release of prostaglandin and 
collagenase from synovial cells. Polymorphism associated with AD [66].
PLAU plasminogen activator, urokinase. Polymorphisms associated with AD [68].
stress response genes 
altered in aged mouse 
brain [28].
APOD apolipoprotein D. APOD occurs in the macromolecular complex with lecithin-cholesterol acyltransferase. It is 
probably involved in the transport and binding of bilin. Appears to be able to transport a variety of ligands in a 
number of different contexts.
CRYAB alpha B2 crystallin. May contribute to the transparency and refractive index of the lens.
CSNK1D casein-kinase 1 delta. Casein kinases are operationally defined by their preferential utilization of acidic proteins 
such as caseins as substrates. It can phosphorylate a large number of proteins. Participates in Wnt signaling.
CTNNB1 catenin (cadherin-associated protein), beta 1, 88 kDa. Involved in the regulation of cell adhesion and in signal 
transduction through the Wnt pathway.
CTSD cathepsin D. Acid protease active in intracellular protein breakdown. Involved in the pathogenesis of several 
diseases such as breast cancer and possibly Alzheimer's disease.
CTSH cathespin H. Important for the overall degradation of proteins in lysosomes.
CTSS cathespin S. Thiol protease. The bond-specificity of this proteinase is in part similar to the specificities of cathepsin 
L and cathepsin N.
CTSZ cathepsin Z. Exhibits carboxy-monopeptidase as well as carboxy-dipeptidase activity.
DDIT3 gadd153 DNA-damage inducible transcript 3. Inhibits the DNA-binding activity of C/EBP and LAP by forming 
heterodimers that cannot bind DNA.
DNAJB1 DnaJ (Hsp40) homolog, subfamily B, member 1. Interacts with HSP70 and can stimulate its ATPase activity. 
Stimulates the association between HSC70 and HIP.
DNAJB2 DnaJ (Hsp40) homolog, subfamily B, member 2.
FOSB FBJ murine osteosarcoma viral oncogene homolog B. FosB interacts with Jun proteins enhancing their DNA 
binding activity.
GFAP glial fibrillary acidic protein. A class-III intermediate filament, is a cell-specific marker that, during the development 
of the central nervous system, distinguishes astrocytes from other glial cells.
JUNB jun B proto-oncogene. Transcription factor involved in regulating gene activity following the primary growth factor 
response. Binds to the DNA sequence 5'-TGA [CG]TCA-3'.
NDRG1 N-myc downstream regulated gene 1. Cycophilin C associated protein. May have a growth inhibitory role.
NR2C2 nuclear receptor subfamily 2, group C, member 2. Orphan nuclear receptor. May regulate gene expression during 
the late phase of spermatogenesis.
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SAA2 serum amyloid A2.
UCHL1 ubiquitin carboxyl-terminal esterase L1 (ubiquitin thiolesterase). Ubiquitin-protein hydrolase is involved both in the 
processing of ubiquitin precursors and of ubiquinated proteins. This enzyme is a thiol protease that recognizes and 
hydrolyzes a peptide bond at the C-terminal glycine of ubiquitin.
VIM vimentin. Vimentins are class-III intermediate filaments found in various non-epithelial cells, especially mesenchymal 
cells.
Mitochondria complex 1
NDUFA1
NDUFA2
NDUFA3
NDUFA4
NDUFA5
NDUFA6
NDUFA7
NDUFA8
NDUFA9
NDUFA10
NDUFAB1
NDUFB1
NDUFB2
NDUFB3
NDUFB4
NDUFB5
NDUFB6
NDUFB7
NDUFB8
NDUFB9
NDUFB10
NDUFC1
NDUFC2
NDUFS1
NDUFS2
NDUFS3
NDUFS4
NDUFS5
NDUFS6
NDUFS7
NDUFS8
NDUFV1
NDUFV2
NDUFV3
Table 5: Cognitive Ageing Candidate Genes (expressed in the brain). (Continued)
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